Smoking Cessation Vaccine Fails to Deliver in Phase III
Stock in Nabi Biopharmaceuticals Inc. plunged 66.4 percent Monday on news that its smoking cessation vaccine, NicVAX, missed its primary endpoint in a Phase III trial. Participants in the double-blinded, placebo-controlled trial of 1,000 people quit smoking at a similar rate whether they were randomized to the vaccine or placebo group, about 11 percent. The company expressed surprise and disappointment, and is awaiting results of its second Phase III trial.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter